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Malignant ﬁbrous histiocytoma (MFH) of the small intestine is an extremely rare condition. It occurs most commonly in the
extremities and the trunk. We report a case of a 67-year-old woman who admitted with fever, myalgia, and altered status. After
thorough investigation, a tumor of the jejunum was found. The patient underwent complete surgical removal of the tumor. A
diagnosis of MFN (undiﬀerentiated high-grade pleomorphic sarcoma) was made. The patient received adjuvant chemotherapy
with Gemcitabine. Two years after the operation, the patient died due to recurrence of the disease. MFH of the small intestine is
anextremely rare neoplasmwith anaggressive biologicalbehaviour. In this paper, pathogenesis,naturalhistory, andtreatment are
reviewed.
1.Introduction
Malignant ﬁbrous histiocytoma is a soft-tissue tumor sarco-
ma of mesenchymal origin. The site of primary origin tends
to be mainly in the extremities followed by the trunk, the
head, and the neck. It is the most common soft-tissue sarco-
ma with the peak incidence in the seventh decade. Although
MFH is the most common soft-tissue sarcoma in late adult
life,intestinal involvementhasrarelybeenreported. Areview
oftheliteraturerevealed41cases.Thisreport describesacase
of MFH arising in the small intestine [1, 2].
2.CaseReport
A 67-year-old woman was admitted to the department of in-
ternal medicine due to persistent fever (39◦Cm a x ) ,w e i g h t
loss, poor appetite, myalgia, and fatigue. Personal history of
the patient revealed total hysterectomy 28 years ago and ra-
diotherapy due to endometrial cancer.
Physical examination on admission showed slight ab-
dominal distension without tenderness and no mass pal-
pable. Laboratory examination showed 11,400 WBC with
normal diﬀerential count. Total protein level was nor-
mal (7.2U/L), but the globulin level was slightly elevated
(3.94mg/dL). Tumor markers (CEA, Ca 19-9, Ca 125, CA
15-3, alpha-foetoprotein) were within normal values. Ultra-
sonography of the abdomen revealed a mass at the left lower
abdominal cavity. Computed tomography of the thorax was
normal, while the one of the abdomen and the retroperi-
toneal space revealed a tumor within the lesser pelvic cavity
in the proximity of the small intestine (Figure 1).
At surgery, we found a tumor mass originating from the
wall ofthe small intestine (jejunum), invading the mesentery
(Figures 2 and 3). There was no sign of intraabdominal
spread, and wide resection of the tumor with intestinal side
to side anastomosis was performed.
The tumor measured 6, 4 × 4 × 4, 5cm, and the cut sur-
face of the tumorwas whitish-brown in colorand had a solid
appearance. Microscopically, the tumor mass had a submu-
cosal location, and it had invaded the muscular layer with no
signs of serosal, perineural, or vascular invasion (Figure 4).
The histopathological examination demonstrated a stori-
form pattern of growth with lymphocytic and neutrophilic
inﬁltrates and dispersed atypical, spindle- or oval-shaped2 Case Reports in Medicine
Figure 1: Preoperative CT examination of the patient.
Figure 2: Intraoperative ﬁnding.
Figure 3: Intraoperative ﬁnding.
Figure 4: Microscopy with H and E staining ×40, left up ×400.
cells. Pleomorphic mono-, multinucleated cells with bizarre
nuclei were also intermingled in the lesion. Mitotic ﬁgures
were pronounced immunohistochemically, and the tumor
cells were positive to vimentin and CD-68 antigen but nega-
tive to desmin, S100 protein, cytokeratins AE1/AE3, CD117,
and CD34 antigen (Figure 5).
Pathology diagnosis was storiform/pleomorphic MFH
(current WHO classiﬁcation: undiﬀerentiated high-grade
pleomorphic sarcoma).
The postoperativeperiod wasuneventful,and thepatient
was discharged one week after the operation. The patient re-
ceived adjuvant chemotherapy based on Gemcitabine. Un-
fortunately, two years after the operation, she suﬀered from
recurrence of the tumor with lung metastasis and died.
3.Discussion
Malignant soft-tissue tumors of the small intestine are ex-
tremely rare. The most common type is leiomysarcoma [3].
MFH was ﬁrst described as malignant histiocytoma and
ﬁbrous xanthoma by Ozello et al. in 1963 and was estab-
lished by O’Brien and Stout in 1964 to describe soft-tissue
sarcomasarising fromﬁbroblastsandhistiocytes[4,5].MFH
has varied histology morphology, but the classic form is
composed of spindle-shaped and round histiocytes arranged
in storiform pattern and accompanied by inﬂammatory cells
as in our case.
MFH is considered to be a rare malignancy of visceral
organs. It has been described in the lung, kidney, liver, stom-
ach, duodenum, pancreas, colon, and anal canal. It usually
occurs in the extremities, presenting as a painless mass,
and less commonly in the retroperitoneal space, associated
with weight loss and increased intra-abdominal pressure
[6]. Five histological subtypes of MFH have been described:
pleomorphic storiform and myxoid (most common types),
giant cell, inﬂammatory, and angiomatoid [7].
The karyotypic abnormalities in MFH are usually com-
plex, with multiple numerical and structural rearrange-
ments. Schmidt reported that chromosomes 1, 3, 6, 9, 12, 16,Case Reports in Medicine 3
Figure 5: Immunohistochemistry with vimentin (left) and CD
68/100 (right).
18, and 20 are involved in structural aberrations and that
thebreakpoint regions are most frequentlyobserved in1p32,
3p25, and in the centromeric region of chromosomes 1 and
16. The pathogenesis of MFH has not been clariﬁed to date.
However, it has been recognized as a complication of ra-
diation, resulting from chronic postoperative repair, trauma,
surgical incisions, or burn scars [8, 9].
The diagnosis of MFH depends on an accurate diﬀer-
ential diagnosis from other sarcomas, observation of kary-
omorphism and diﬀerential ﬁgures, and positive results on
immunohistological staining. It was reported that MFH fre-
quently expresses vimentin, actin, CD-68, and α 1-anti-
trypsin and α 1-antichymotrypsin. The diﬀerential diagnosis
of MFH should include pleomorphic liposarcoma and rhab-
domyosarcoma. The former lacks the storiform pattern and
shows evidence of cellular diﬀerentiation, while the latter
shows cross striations on histological examination [10].
Liesveld et al. reported that patients with MFH have leu-
kocytosis, leukemoid reaction, and paraneoplastic syndrome
because of various cytokines produced by tumor cells. Thus,
postoperative recurrent leukocytosis and elevated CRP level
might be predictors for recurrence of MFH [11].
The biological behaviour of malignant ﬁbrous histiocy-
toma is extremely aggressive, and the prognosis is presum-
ably poor, mainly depending on the size and histological
grading.
The treatment for MFH is early and complete surgi-
cal excision with en-bloc regional lymph node dissection.
Chemotherapy (Doxorubicin or Gemcitabine or combina-
tion of Doxorubicin and Decarbazine, and Doxorubicin,
Mesna, and Ifosfamide) or radiation is recommended in
those patients in whom there is vascular or lymphatic inﬁl-
tration. Zagars et al. reported that adjuvant chemotherapy
cannot minimize the rate of metastasis [12]. Patients with
myxoid tumors do not require systemic therapy. However,
patients with nonmyxoid disease exceeding 5cm are at a
signiﬁcant risk of developing metastases, and the develop-
mentofeﬀectiveadjuvanttreatment isanimportant research
goal [12]. Most of the reports suggest that the prognosis
associated with colonic MFH is poor. Weiss and Enzinger’s
analysis of MFH showed that the 2-year survival rate of
patients with pleomorphic/storiform type of MFH is 60%
and the rate of metastases is 42% [6].
In conclusion, primary intestinal histiocytoma is an ex-
tremelyrareneoplasmwithanaggressivebiologicalbehavior.
Complete surgical resection is preferred, and adjuvant
chemotherapy or radiotherapy may be advisable. Due to the
recurrence, lifelong surveillance should be carried out.
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